CYP24A1 and neoplasm: All synthesized compounds were tested in enzyme inhibition assays against the widespread and cytosolic hCA I and II enzymes and the tumor-associated and transmembrane hCA IX and XII enzymes with extracellular catalytic domains (Table 1, Figure 1).